Ophthalmology prior authorization at EmblemHealth
PA workflow, documentation criteria, and peer-to-peer prep — for prescribers and PA staff
EmblemHealth ophthalmology PA at a glance
EmblemHealth reviews ophthalmology PA submissions against its medical policy library, with rules drawn primarily from AAO (American Academy of Ophthalmology) Preferred Practice Patterns. EmblemHealth-specific context: NY-based; operates HIP (HMO) and GHI (PPO) brands; ~3M members. Administers the NYC municipal employee GHI-CBP plan — high-volume source of OON disputes for retirees. NY DFS oversight; ConnectiCare is the Connecticut subsidiary.
Documentation packet — what to send
- Diagnosis with ICD-10 (nAMD, DME, RVO, mCNV)
- OCT scan with central macular thickness
- Fluorescein angiography or OCT-A confirming CNV/leakage where required
- Prior anti-VEGF history (drug, doses, intervals, response)
- Visual acuity (Snellen + ETDRS letters)
Common denial patterns to pre-empt
Patterns observed in ophthalmology across payers, and where EmblemHealth's book of business overlaps:
- Anti-VEGF: brand vs compounded bevacizumab (significant cost differential)
- Step therapy: bevacizumab before aflibercept/faricimab
- Dosing interval not policy-compliant (e.g., monthly vs every-8-weeks)
- Diagnosis confirmation (OCT, fluorescein angiogram) not documented
- Loading dose schedule not followed
Appeal angles when EmblemHealth denies
- AAO Preferred Practice Pattern citation
- Anatomic outcome (OCT central macular thickness)
- Functional outcome (visual acuity by ETDRS letters)
- Documented prior anti-VEGF failure
- Diabetic macular edema vs neovascular AMD vs RVO — distinct PA criteria per indication
Peer-to-peer prep
- Bring the latest OCT scan (printed or open in EHR)
- Quote the AAO PPP by year + indication
- For step-therapy through bevacizumab: cite documented failure or contraindication if requesting aflibercept/faricimab first-line
- State whether the dosing is loading (monthly × 3) or maintenance (PRN vs treat-and-extend vs fixed)
Drug-specific PA criteria at EmblemHealth
Deep dives on each drug's PA criteria at EmblemHealth:
Frequently asked questions
What documentation does EmblemHealth need for ophthalmology prior authorizations?
EmblemHealth's PA packet for ophthalmology typically includes: Diagnosis with ICD-10 (nAMD, DME, RVO, mCNV); OCT scan with central macular thickness; Fluorescein angiography or OCT-A confirming CNV/leakage where required; Prior anti-VEGF history (drug, doses, intervals, response). AAO (American Academy of Ophthalmology) Preferred Practice Patterns citations strengthen the submission.
What's the turnaround at EmblemHealth?
EmblemHealth standard decision: 30 days. Expedited (urgent care): 72 hours per 45 CFR §147.136. Internal appeal window if denied: 180 days.
Which ophthalmology drugs does EmblemHealth most often PA-restrict?
Top targets in ophthalmology: aflibercept, faricimab, ranibizumab. Each follows the per-drug step therapy + documentation requirements published in EmblemHealth's medical policy library.
How do I prep a peer-to-peer with EmblemHealth in ophthalmology?
Bring the latest OCT scan (printed or open in EHR) Quote the AAO PPP by year + indication Have the policy URL and the patient's chart open before the call.
Generate a Ophthalmology PA packet
Open ApprovalHelp — generate a ophthalmology PA packet tailored to EmblemHealth's criteria, with prescriber attestation and supporting citations pre-filled.
Get started →Contact: hello@approvalhelp.com